Activated Charcoal Arsenic Triiodide Arsenic Triox

證據等級: L5

預測適應症: 0 個

Multi-Component Compound Mixture (Arsenic Trioxide et al.): Insufficient Evidence for Repurposing Evaluation

One-Sentence Summary

This candidate is a 12-component compound mixture — including arsenic compounds (arsenic trioxide, arsenic triiodide), a heavy metal element (gold), egg phospholipids, and eight botanical extracts — consistent with a homeopathic or traditional medicine formulation rather than a defined single-entity pharmaceutical. The TxGNN model generated no repurposing predictions for this compound, and the product holds zero US or Taiwan market authorizations. With no original indication on record, no predicted indication, and all safety data absent, a meaningful drug repurposing evaluation is not currently feasible.

Quick Overview

Item	Content
Original Indication	None on record
Predicted New Indication	None identified by TxGNN
TxGNN Prediction Score	Not available
Evidence Level	Below L5 — no predictions generated
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Compound Profile and Evaluation Context

This candidate comprises the following 12 declared ingredients:

#	Ingredient	Category
1	Activated Charcoal	Adsorbent / Detoxifying agent
2	Arsenic Triiodide	Inorganic arsenic salt
3	Arsenic Trioxide	Inorganic arsenic compound (known antineoplastic at therapeutic doses)
4	Artemisia Vulgaris Root	Botanical (mugwort)
5	Chionanthus Virginicus Bark	Botanical (fringe tree)
6	Corallium Rubrum Exoskeleton	Marine-origin material (red coral)
7	Egg Phospholipids	Lipid excipient / nutritional component
8	Gold	Heavy metal element
9	Morella Cerifera Root Bark	Botanical (bayberry)
10	Ornithogalum Umbellatum	Botanical (star of Bethlehem)
11	Petroselinum Crispum	Botanical (parsley)
12	Sanguinaria Canadensis Root	Botanical (bloodroot)

This ingredient profile is characteristic of a homeopathic or complex traditional medicine preparation. TxGNN is designed to evaluate single-entity drugs or defined molecular entities mapped through DrugBank. Because this product has no DrugBank ID, could not be mapped to the knowledge graph, and contains multiple pharmacologically unrelated substances, the model returned no predictions. This is an expected and appropriate null result for a product of this nature, not a data pipeline failure.

There is no established single mechanism of action, no standard indication, and no regulatory approval pathway that applies to this compound as a whole.

Cytotoxicity Note

Applicable due to the presence of Arsenic Trioxide, which at therapeutic concentrations is a recognized cytotoxic antineoplastic agent (approved for acute promyelocytic leukemia, APL).

Item	Content
Cytotoxicity Classification	Mixed: contains one conventional cytotoxic component (arsenic trioxide); remaining ingredients are not classified as cytotoxic
Myelosuppression Risk	Cannot be determined for the compound as a whole; arsenic trioxide monotherapy carries moderate myelosuppression risk
Emetogenicity Classification	Cannot be determined for the compound as a whole
Monitoring Items	If arsenic-containing, monitoring of QTc interval, hepatic and renal function, electrolytes (potassium, magnesium), and complete blood count would be standard for the arsenic component
Handling Protection	Arsenic compounds require cytotoxic handling precautions; the combined formulation should be treated with equivalent caution until classified otherwise

Safety Considerations

Safety data for this compound as a whole is not available. The absence of any market authorization means no approved package insert or formal safety labeling exists for review.

Given the presence of arsenic-containing ingredients, the following general cautions are recognized in the medical literature:

Arsenic trioxide is associated with QT prolongation and risk of fatal arrhythmia
Hepatotoxicity and peripheral neuropathy have been reported with arsenic compounds
Sanguinaria canadensis (bloodroot) contains sanguinarine, which carries mucosal toxicity risk

Formal safety profiling via DrugBank API, TFDA package insert review, and DDI screening should be completed before any further evaluation.

Conclusion and Next Steps

Decision: Hold

Rationale: This candidate is a multi-component mixture for which TxGNN cannot generate meaningful repurposing predictions due to the absence of a DrugBank ID, no approved indication, and no mechanism-of-action data. The compound’s heterogeneous ingredients — ranging from arsenic compounds to botanical extracts — make it structurally incompatible with the current single-entity repurposing pipeline.

To proceed, the following is needed:

Clarify the product identity: Determine whether this is a registered homeopathic product, a compounded preparation, or an experimental formulation; obtain a precise formulation with concentrations for each ingredient
Decompose into individual components: If repurposing research is the goal, evaluate arsenic trioxide separately (DrugBank: DB01169) as it has an established indication and active clinical trial record (APL and potentially other hematologic malignancies)
Obtain DrugBank mapping: At minimum for arsenic trioxide and sanguinaria canadensis, which have the highest pharmacological activity
Safety baseline: Complete TFDA package insert review (if any component is registered), toxicology literature review for arsenic compounds, and full DDI screening for each active ingredient individually
Regulatory classification: Determine whether this compound is classified as a homeopathic medicine, traditional medicine, or compounded drug in the target jurisdiction — this determines which evidence standards apply
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.